We are testing a new treatment called PIT565 for patients with relapsed or refractory B-cell malignancies. The goal is to see if it can improve outcomes for these patients.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed and refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL) and Acute Lymphoblastic Leukaemia (R/R B-ALL) are types of blood cancers that return after treatment or do not respond to initial therapies, requiring new treatment options.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
